Research Papers:

Prognostic effect of adjuvant chemoradiotherapy for patients with gastric cancer: an updated evidence of randomized controlled trials

Mei-Juan Wang, Chao Li, Yue Sun, Fu-Jun Shen and Chun-Bin Wang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:102880-102887. https://doi.org/10.18632/oncotarget.21983

Metrics: PDF 1292 views  |   HTML 1789 views  |   ?  


Mei-Juan Wang1,*, Chao Li1,*, Yue Sun 1, Fu-Jun Shen1 and Chun-Bin Wang1

1Department of Oncology, Yancheng Hospital Affiliated to Medical College of Southeast University and The Third People’s Hospital of Yancheng, Yancheng, Jiangsu, 224001, China

*These authors contributed equally to this work

Correspondence to:

Chun-Bin Wang, email: [email protected]

Keywords: chemoradiotherapy; gastric cancer; survival; prognosis; randomized controlled trial

Received: August 31, 2017     Accepted: October 03, 2017     Published: October 24, 2017


The prognostic effect of chemoradiotherapy in gastric cancer has been evaluated for decades while the results are still in debate and heterogeneous.

We thus comprehensively updated the evidence through systematic review and meta-analysis to evaluate chemoradiotherapy in gastric cancer to determine its effect. Pubmed, EMBASE, and Cochrane Library from the earliest possible year to April 2017 were searched. Randomised controlled trials (RCTs) that assessed the effects of combined chemoradiotherapy for patients with gastric cancer compared with that of single chemotherapy were included. The main outcome measure was 5-year overall survival (OS) and the second was disease-free survival (DFS) or recurrence-free survival (RFS).

Fifteen RCTs involving 3347 patients were included into this meta-analysis. Compared with single chemotherapy, the relative risk (RR) for 5-year OS for chemoradiotherapy was 1.05 (95% CI 0.88 to 1.25), with moderate heterogeneity across eligible trials (I2 = 55.7%, p = 0.016). Subgroup analyses and sensitivity analyses confirmed the consistent findings. We found that significant survival benefit for 5-year DFS/RFS for chemoradiotherapy over single chemotherapy (RR 0.89 95% CI 0.81 to 0.98) for patients with gastric cancer. This updated meta-analysis does not provide strong evidence for a 5-year survival benefit of chemoradiotherapy over chemotherapy alone in patients with gastric cancer. A clear advantage of chemoradiotherapy over chemotherapy has not been established. Further larger RCTs should be conducted to determine its true effect.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21983